🔗 Share this article

As America proceeds with unprecedented revisions to its vaccine guidelines, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by casting doubt on Covid vaccinations during the pandemic and has concentrated on potential fatalities after COVID-19 immunization in her recent time at the FDA.

Planned Shifts to Pediatric Immunization Schedule

Agency leaders had intended to reveal radical revisions to the pediatric immunization program earlier this month, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US out of step with much of the international standard with little proof for benefit. This reveal has been pushed back until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing specific pediatric immunization guidelines in the US to become more similar to Denmark, a nation with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

To date statements, she has continued to focus on vaccination policy – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Qualifications

The appointee has no apparent track record in medication creation, regulation or management, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, said Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in leading a major agency. She has no expertise in drug approvals.”

Past commissioners of the center would “understand regulatory frameworks and the science of drug development”, said Janet Woodcock. “Clearly, she lacks the type of experience that prior appointees who headed CBER have had.”

This division has an immense range of responsibilities at the FDA, the former commissioner pointed out.

“Everybody just pays attention on the innovative therapies, but the off-patent medication office authorizes thousands of generic medications. There is also a biologic copycat branch, OTC medication office and so forth, and every single one must be managed,” Woodcock noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a major administrative aspect to the job, which oversees in excess of 5,000 staff members. “It’s a massive management job, if you do it right,” Woodcock added.

Official Statement and Disputed Policies

When asked about questions about Høeg’s qualifications and whether this assignment represents more teamwork among FDA leaders on immunizations, a representative responded that the “concerns stem from inaccurate premises”.

“Her experience aligns with the responsibilities of her job,” the official said, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new priority voucher program, a controversial rapid drug-approval program that reportedly troubled her former heads. “By what process are these medications being selected for this expedited pathway? Who takes the choices?” Howard questioned. “There’s a lot of lack of transparency occurring at the FDA right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards more relaxed oversight of all drugs, except for shots.”

Public History on Immunizations

Concerning vaccines, Høeg has a clearer, if concerning, history, critics have noted. She authored a analysis using unconfirmed public submissions to estimate the incidence of myocarditis after Covid immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are riskier than they are.

Part of her “wish list” for the incoming government featured changing guidelines for novel immunizations and ending “non-essential” immunizations, she remarked after the election on a audio program. At the FDA, Høeg has allegedly suggested barring adolescent males from obtaining Covid vaccines.

“She’s an thorough true believer who starts off with her conclusions and tailors the evidence to accommodate the evidence in a highly deceptive, untruthful manner,” Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg aligned with fellow dissenters, {like|